HUTCHMED (China) Limited

NASDAQ:HCM

Drug Manufacturers - Specialty & Generic

Healthcare
$13.99 +1.58%

+$0.16 today

Market cap
$2.44B
Beta
0.37
P/E (TTM)
46.2
EPS (TTM)
$0.05
52W Low $10.01High $19.50

Volume 0.04M

Average 0.04M

HCM Income Before Tax

Profit after all operating and non-operating items but before income tax.

HUTCHMED (China) LimitedNASDAQ: HCM

Income Before Tax · Q2 FY2025 · quarter ended Jun 2025

Income before tax growth accelerates

Q2 FY2025 income before tax of $259.36M rose 1685.5% year over year, ahead of the +1525.1% change in trailing-twelve-month income before tax. Sequentially, it rose 0.0% from the prior quarter.

Context

  • Income before tax amounted to 95.0% of revenue in FY2025, up 87.8 pp from a year earlier.
  • Income before tax increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +1685.5% holds above the trailing-twelve-month pace of +1525.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2025
$259.36M+0.0% QoQ
Last fiscal yearDec 2025
$522.72M+1052.3% YoY
LTMJun 2025
$535.03M+1525.1% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1685.5%——
1 year+1052.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
522.72M USD
Year-over-year change
+1052.3%

Income Before Tax vs competitors

How HCM compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1525.1% is the highest of 9, against a peer median of +21.9%.
  • Income before tax amounts to 88.8% of revenue for HCM, versus a peer median of 52.2%.
HCM Competitors
Income Before Tax for HCM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$1.97B USD+55.8%+46.5%33.8%
EXELExelixis, Inc.LTM Jul 2026$1.04B USD+33.5%+59.0%42.5%
GMABGenmab A/SLTM Jun 2026$906.11M USD—-44.2%21.9%
HCMHUTCHMED (China) LimitedLTM Jun 2025$535.03M USD+1525.1%—88.8%
LEGNLegend Biotech CorporationLTM Sep 2026$32.2M USD+114.5%—2.4%
ANLAdlai Nortye Ltd.LTM Jun 2024-$53.42M USD——823.1%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026-$140.06M USD+54.3%—62.2%
ZLABZai Lab LimitedLTM Jun 2026-$190.72M USD+10.3%—42.4%
RCUSArcus Biosciences, Inc.LTM Jun 2026-$452M USD-47.7%—386.3%
AAPGAscentage Pharma Group InternationalFY2025-CN¥1.2B CNY-204.2%—215.3%
BNTXBioNTech SELTM Jun 2026-€1.64B EUR-321.6%—61.9%
Peer median (excluding HCM) —+21.9%+46.5%52.2%

Competitors are the stored peer set for HCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue356.13M426.41M838M630.2M549.96M
Cost of Revenue258.23M311.1M384.45M348.88M337.24M
Gross Profit97.89M115.31M453.55M281.32M212.72M
Gross Margin27.5%27.0%54.1%44.6%38.7%
Research & Development207.45M267.59M303.06M213.37M164.15M
Selling, General & Admin127.13M136.11M133.18M112.91M103.3M
Operating Expenses426.21M523M436.23M321.93M267.45M
Depreciation & Amortization7.19M8.66M8.21M12.34M13.34M
EBITDA(207.96M)(401.11M)26.58M(31.36M)(41.38M)
EBITDA Margin-58.4%-94.1%3.2%-5.0%-7.5%
Operating Income(328.32M)(409.77M)18.38M(43.71M)(54.73M)
Operating Margin-92.2%-96.1%2.2%-6.9%-10.0%
Interest Income2.08M9.6M36.15M40.08M50.01M
Interest Expense592K652K759K2.87M2.87M
Other Income / Expenses173.19M51.52M87.23M89.07M577.45M
Income Before Tax(155.33M)(360.24M)105.6M45.36M522.72M
Pre-Tax Margin-43.6%-84.5%12.6%7.2%95.0%
Income Tax Expense11.92M(283K)4.51M7.19M63.78M
Net Income(194.65M)(360.84M)100.78M37.73M458.12M
Net Margin-54.7%-84.6%12.0%6.0%83.3%
EPS (Basic)(1.25)(2.15)0.600.222.65
EPS (Diluted)(1.25)(2.15)0.600.222.60
Weighted Avg Shares158.54M169.43M169.93M171.07M171.66M
Weighted Avg Shares (Diluted)158.54M169.43M173.84M174.57M174.58M

HUTCHMED (China) Limited

NASDAQ:HCM

Intrinsic Alpha fair value

Locked

Current Price

$13.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.